Department Metrics

• Mathematical Model-Guided Adoptive Immunotherapy in Bladder Cancer
  Sponsor: Nat Institutes of Health
  PI (Contact):Rejniak, K.,PI (MPI):Pilon-Thomas, S.
• Developing Mathematical Model Driven Optimized Recurrent Glioblastoma Therapies
  Sponsor: Nat Institutes of Health
  PI (Contact):Enderling, H.,PI (MPI):Yu, M.
• Characterizing Cytotoxic Therapy Induced Shifts in the Cost-to-Benefit Ratio of High Ploidy
  Sponsor: Nat Institutes of Health
  PI:Andor, N.
• A framework to integrate live-cell imaging with single-cell sequencing and learn how cells adapt to new environments
  Sponsor: Nat Institutes of Health
  PI:Andor, N.
• Engineering Model-Based Systems to Monitor and Steer Subclonal Dynamics
  Sponsor: Nat Institutes of Health
  PI:Andor, N.
• Development of Adoptive T-Cell Therapy in Bladder Cancer Incorporating Patient-Specific Tumor Microenvironment
  Sponsor: US Army
  PI:Rejniak, K.
• The Polyaneuploid Cancer Cell State Mediates Multitherapy Resistance in Cancer
  Sponsor: US Army
  PI:Brown, J.
• Modeling the Role and Regulation of Reactive Stroma in Breast Ductal Carcinoma Microinvasions
  Sponsor: Nat Institutes of Health
  PI:Rejniak, K.
• The Delta Ecology of NSCLC Treatment
  Sponsor: Nat Institutes of Health
  PI (Contact):Anderson, A.,PI (MPI):Gatenby, R.,Project PI:Marusyk, A.,Core PI/Director:Brown, J.
• Using Patient-Reported Outcome Dynamics to Predict Response to Immunotherapy in Non-Small Cell Lung Cancer
  Sponsor: Moffitt Cancer Center
  PI:Brady, R.
• Evolutionary Therapy in ER+ Breast Cancer Guided by Second-Order Reasoning
  Sponsor: Moffitt Cancer Center
  PI:West, J.
• Virtual patient cohort generation for radiation therapy using probability distribution convolution
  Sponsor: Moffitt Cancer Center
  PI:West, J.
• Testing Karyotype Evolution as a Biomarker of Immune Fitness and ICI Therapy Response in the Brain Tumor Microenvironment
  Sponsor: Moffitt Cancer Center
  PI:Andor, N.,CO-PI:Smalley, I.
• Evolutionary Game Theory in Prostate Cancer Bone Metastasis: Elucidating the Dual Role of MSCs in Tumor Cell Dynamics
  Sponsor: Moffitt Cancer Center
  PI (Contact):Basanta Gutierrez, D.
• STEER: Strategy for Therapeutic Extinction of Evolving Resistance in lung cancer
  Sponsor: Moffitt Cancer Center
  PI (Contact):Robertson-Tessi, M.,CO-PI:Marusyk, A.
• Moffitt Mathematical Oncology HIP Program
  Sponsor: FL Dept of Education
  PI:Brady, R.

CLINICAL TRIAL 21139
A Phase IIA Study of Sequential ("first strike, second strike") Therapies, Modeled on Evolutionary Dynamics of Anthropocene Extinctions, for High Risk Metastatic Castration Sensitive Prostate Cancer
Condition: Genitourinary
Intervention: Abiraterone acetate (); Apalutamide (); Decapeptyl SR (Triptorelin); Degarelix (); Eligard (Leuprolide); Enzalutamide (Xtandi); Leuprolide (); Relugolix (Orgovyx); Taxotere (docetaxel); Tislelizumab (); Triptorelin (); Zytiga (Abiraterone acetate); docetaxel (); goserelin acetate (Zoladex); prednisone ()

CLINICAL TRIAL 21559
A Phase 1/2 Study of EPI-7386 in Combination with Enzalutamide Compared with Enzalutamide Alone in Subjects with Metastatic Castration-Resistant Prostate Cancer
Condition: Genitourinary
Intervention: EPI-7386 (); Enzalutamide (Xtandi); Not Applicable ()

CLINICAL TRIAL 22003
A Phase II Randomized Study of Sipuleucel-T with or without Continuing New Hormonal Agents (NHA) in Metastatic Prostate Cancer with PSA Progression while on NHA and LHRH Analog
Condition: Genitourinary
Intervention: Abiraterone (); Apalutamide (); Enzalutamide (Xtandi); Provenge (Sipuleucel-T); Sipuleucel-T (); prednisone ()

CLINICAL TRIAL 22344
A Phase I Clinical Trial of an Infusion of Autologous gamma delta T cells Genetically Engineered with a Chimeric Receptor to Target the Prostate Stem Cell Antigen in Patients with Metastatic Castration Resistant Prostate Cancer
Condition: Genitourinary
Intervention: MSGV1-PSCA-8T28Z (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)

• Gallagher K, Strobl MA, Park DS, Spoendlin FC, Gatenby RA, Maini PK, Anderson AR. Mathematical Model-Driven Deep Learning Enables Personalized Adaptive Therapy. Cancer Res. 2024 Apr. Pubmedid: 38569183.
• Ojwang' AME, Bazargan S, Johnson JO, Pilon-Thomas S, Rejniak KA. Histology-guided mathematical model of tumor oxygenation: sensitivity analysis of physical and computational parameters. bioRxiv. 2024 Mar. Pubmedid: 38496532. Pmcid: PMC10942376.
• Hu A, Ojwang' AME, Olumoyin KD, Rejniak KA. Visualizing the Spatio-Temporal Dynamics of Clonal Evolution with LinG3D software. bioRxiv. 2024 Mar. Pubmedid: 38496472. Pmcid: PMC10942425.
• Bishop RT, Miller AK, Froid M, Nerlakanti N, Li T, Frieling JS, Nasr MM, Nyman KJ, Sudalagunta PR, Canevarolo RR, Silva AS, Shain KH, Lynch CC, Basanta D. The bone ecosystem facilitates multiple myeloma relapse and the evolution of heterogeneous drug resistant disease. Nat Commun. 2024 Mar.15(1):2458. Pubmedid: 38503736. Pmcid: PMC10951361.
• Pierik L, McDonald P, Anderson ARA, West J. Second-Order Effects of Chemotherapy Pharmacodynamics and Pharmacokinetics on Tumor Regression and Cachexia. Bull Math Biol. 2024 Mar.86(5):47. Pubmedid: 38546759.
• West J, Rentzeperis F, Adam C, Bravo R, Luddy KA, Robertson-Tessi M, Anderson ARA. Tumor-immune metaphenotypes orchestrate an evolutionary bottleneck that promotes metabolic transformation. Front Immunol. 2024 Feb.15:1323319. Pubmedid: 38426105. Pmcid: PMC10902449.
• Marzban S, Srivastava S, Kartika S, Bravo R, Safriel R, Zarski A, Anderson A, Chung CH, Amelio AL, West J. Spatial interactions modulate tumor growth and immune infiltration. bioRxiv. 2024 Mar. Pubmedid: 38370722. Pmcid: PMC10871273.
• Mathur S, Chen S, Rejniak KA. Exploring chronic and transient tumor hypoxia for predicting the efficacy of hypoxia-activated pro-drugs. NPJ Syst Biol Appl. 2024 Jan.10(1):1. Pubmedid: 38182612. Pmcid: PMC10770176.
• Seyedi S, Teo R, Foster L, Saha D, Mina L, Northfelt D, Anderson KS, Shibata D, Gatenby R, Cisneros LH, Troan B, Anderson ARA, Maley CC. Testing Adaptive Therapy Protocols Using Gemcitabine and Capecitabine in a Preclinical Model of Endocrine-Resistant Breast Cancer. Cancers (Basel). 2024 Jan.16(2). Pubmedid: 38254748. Pmcid: PMC10813385.
• Mohsin N, Enderling H, Brady-Nicholls R, Zahid MU. Simulating tumor volume dynamics in response to radiotherapy: Implications of model selection. J Theor Biol. 2024 Jan.576:111656. Pubmedid: 37952611.
• Axenie C, López-Corona O, Makridis MA, Akbarzadeh M, Saveriano M, Stancu A, West J. Antifragility as a complex system's response to perturbations, volatility, and time. ArXiv. 2023 Dec. Pubmedid: 38196741. Pmcid: PMC10775345.
• Brown JS, Amend SR, Austin RH, Gatenby RA, Hammarlund EU, Pienta KJ. Updating the Definition of Cancer. Mol Cancer Res. 2023 Nov.21(11):1142-1147. Pubmedid: 37409952. Pmcid: PMC10618731.
• Miroshnychenko D, Miti T, Kumar P, Miller A, Laurie M, Giraldo N, Bui MM, Altrock PM, Basanta D, Marusyk A. Stroma-Mediated Breast Cancer Cell Proliferation Indirectly Drives Chemoresistance by Accelerating Tumor Recovery between Chemotherapy Cycles. Cancer Res. 2023 Nov.83(22):3681-3692. Pubmedid: 37791818. Pmcid: PMC10646478.
• Welch DL, Fridley BL, Cen L, Teer JK, Yoder SJ, Pettersson F, Xu L, Cheng CH, Zhang Y, Alexandrow MG, Xiang S, Robertson-Tessi M, Brown JS, Metts J, Brohl AS, Reed DR. Modeling phenotypic heterogeneity towards evolutionarily inspired osteosarcoma therapy. Sci Rep. 2023 Nov.13(1):20125. Pubmedid: 37978271. Pmcid: PMC10656496.
• Poonja S, Forero Pinto A, Lloyd MC, Damaghi M, Rejniak KA. Dynamics of Fibril Collagen Remodeling by Tumor Cells: A Model of Tumor-Associated Collagen Signatures. Cells. 2023 Nov.12(23). Pubmedid: 38067116. Pmcid: PMC10705683.
• Strobl MAR, Gallaher J, Robertson-Tessi M, West J, Anderson ARA. Treatment of evolving cancers will require dynamic decision support. Ann Oncol. 2023 Oct.34(10):867-884. Pubmedid: 37777307.
• Bukkuri A, Pienta KJ, Amend SR, Austin RH, Hammarlund EU, Brown JS. The contribution of evolvability to the eco-evolutionary dynamics of competing species. Ecol Evol. 2023 Oct.13(10):e10591. Pubmedid: 37829179. Pmcid: PMC10565728.
• Chancellor S, Grasse B, Sakmar T, Scheel D, Brown JS, Santymire RM. Exploring the Effect of Age on the Reproductive and Stress Physiology of Octopus bimaculoides Using Dermal Hormones. Animals (Basel). 2023 Oct.13(19). Pubmedid: 37835721. Pmcid: PMC10571824.
• Bazargan S, Bunch B, Ojwang' AME, Blauvelt J, Landin A, Ali J, Abrahams D, Cox C, Hall AM, Beatty MS, Poch M, Rejniak KA, Pilon-Thomas S. Targeting myeloid-derived suppressor cells with gemcitabine to enhance efficacy of adoptive cell therapy in bladder cancer. Front Immunol. 2023 Oct.14:1275375. Pubmedid: 37901214. Pmcid: PMC10602731.
• Nowicka Z, Rentzeperis F, Beck R, Tagal V, Pinto AF, Scanu E, Veith T, Cole J, Ilter D, Viqueira WD, Teer JK, Maksin K, Pasetto S, Abdalah MA, Fiandaca G, Prabhakaran S, Schultz A, Ojwang M, Barnholtz-Sloan JS, Farinhas JM, Gomes AP, Katira P, Andor N. Interactions between ploidy and resource availability shape clonal interference at initiation and recurrence of glioblastoma. bioRxiv. 2023 Oct. Pubmedid: 37905142. Pmcid: PMC10614845.
• Pradeu T, Daignan-Fornier B, Ewald A, Germain PL, Okasha S, Plutynski A, Benzekry S, Bertolaso M, Bissell M, Brown JS, Chin-Yee B, Chin-Yee I, Clevers H, Cognet L, Darrason M, Farge E, Feunteun J, Galon J, Giroux E, Green S, Gross F, Jaulin F, Knight R, Laconi E, Larmonier N, Maley C, Mantovani A, Moreau V, Nassoy P, Rondeau E, Santamaria D, Sawai CM, Seluanov A, Sepich-Poore GD, Sisirak V, Solary E, Yvonnet S, Laplane L. Reuniting philosophy and science to advance cancer research. Biol Rev Camb Philos Soc. 2023 Oct.98(5):1668-1686. Pubmedid: 37157910.
• Chahoud J, Anderson ARA, Zhang J, Brown J, Gatenby RA. Evolutionary Dynamics and Intermittent Therapy for Metastatic Cancers. J Clin Oncol. 2023 Oct.41(28):4469-4471. Pubmedid: 37418680. Pmcid: PMC10553063.
• Gillis N, Padron E, Wang T, Chen K, DeVos JD, Spellman SR, Lee SJ, Kitko CL, MacMillan ML, West J, Tang YH, Teng M, McNulty S, Druley TE, Pidala JA, Lazaryan A. Pilot Study of Donor-Engrafted Clonal Hematopoiesis Evolution and Clinical Outcomes in Allogeneic Hematopoietic Cell Transplantation Recipients Using a National Registry. Transplant Cell Ther. 2023 Oct.29(10):640.e1-640.e8. Pubmedid: 37517612. Pmcid: PMC10592088.
• Bukkuri A, Pienta KJ, Austin RH, Hammarlund EU, Amend SR, Brown JS. A mathematical investigation of polyaneuploid cancer cell memory and cross-resistance in state-structured cancer populations. Sci Rep. 2023 Sep.13(1):15027. Pubmedid: 37700000. Pmcid: PMC10497555.
• Seyedi S, Teo R, Foster L, Saha D, Mina L, Northfelt D, Anderson KS, Shibata D, Gatenby R, Cisneros L, Troan B, Anderson ARA, Maley CC. Testing Adaptive Therapy Protocols using Gemcitabine and Capecitabine on a Mouse Model of Endocrine-Resistant Breast Cancer. bioRxiv. 2023 Sep. Pubmedid: 37781632. Pmcid: PMC10541126.
• Gallaher J, Strobl M, West J, Gatenby R, Zhang J, Robertson-Tessi M, Anderson ARA. Intermetastatic and Intrametastatic Heterogeneity Shapes Adaptive Therapy Cycling Dynamics. Cancer Res. 2023 Aug.83(16):2775-2789. Pubmedid: 37205789. Pmcid: PMC10425736.
• Bhatt A, Schabath MB, Hoogland AI, Jim HSL, Brady-Nicholls R. Patient-Reported Outcomes as Interradiographic Predictors of Response in Non-Small Cell Lung Cancer. Clin Cancer Res. 2023 Aug.29(16):3142-3150. Pubmedid: 37233986. Pmcid: PMC10425729.
• Capp JP, Thomas F, Marusyk A, M Dujon A, Tissot S, Gatenby R, Roche B, Ujvari B, DeGregori J, Brown JS, Nedelcu AM. The paradox of cooperation among selfish cancer cells. Evol Appl. 2023 Jul.16(7):1239-1256. Pubmedid: 37492150. Pmcid: PMC10363833.
• Gatenbee CD, Baker AM, Prabhakaran S, Swinyard O, Slebos RJC, Mandal G, Mulholland E, Andor N, Marusyk A, Leedham S, Conejo-Garcia JR, Chung CH, Robertson-Tessi M, Graham TA, Anderson ARA. Virtual alignment of pathology image series for multi-gigapixel whole slide images. Nat Commun. 2023 Jul.14(1):4502. Pubmedid: 37495577. Pmcid: PMC10372014.
• Veith T, Schultz A, Alahmari S, Beck R, Johnson J, Andor N. Mathematical Modeling of Clonal Interference by Density-Dependent Selection in Heterogeneous Cancer Cell Lines. Cells. 2023 Jul.12(14). Pubmedid: 37508513. Pmcid: PMC10378185.
• Howell-Stephens J, Potratz EJ, Brown JS, Bernier D, Santymire RM. Integrating Measures of Fecal Glucocorticoid Metabolites and Giving-Up Densities to Assess Adrenocortical Activity and Well-Being in Zoo-Housed Three-Banded Armadillos (Tolypeutes matacus). Animals (Basel). 2023 Jun.13(12). Pubmedid: 37370485. Pmcid: PMC10295497.
• Stein A, Salvioli M, Garjani H, Dubbeldam J, Viossat Y, Brown JS, Staňková K. Stackelberg evolutionary game theory: how to manage evolving systems. Philos Trans R Soc Lond B Biol Sci. 2023 May.378(1876):20210495. Pubmedid: 36934755. Pmcid: PMC10024980.